|
CA2326389C
(en)
*
|
1998-04-21 |
2007-01-23 |
Micromet Gesellschaft Fur Biomedizinische Forschung Mbh |
Novel cd19xcd3 specific polypeptides and uses thereof
|
|
JP3425536B2
(ja)
|
1999-04-21 |
2003-07-14 |
株式会社チップトン |
コーティング装置
|
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
|
US8076459B2
(en)
*
|
2003-10-16 |
2011-12-13 |
Micromet Ag |
Multispecfic deimmunized CD3-binders
|
|
BRPI0507649A
(pt)
*
|
2004-02-16 |
2007-07-10 |
Micromet Ag |
molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit
|
|
CN101031655A
(zh)
|
2004-07-26 |
2007-09-05 |
陶氏环球技术公司 |
通过株工程改进蛋白表达的方法
|
|
CA2606081C
(en)
|
2005-04-26 |
2013-09-17 |
Markus M. Heiss |
Combination of the application of antibodies for immunostimulation together with glucocorticoids
|
|
CN103145837A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
|
US8236308B2
(en)
|
2005-10-11 |
2012-08-07 |
Micromet Ag |
Composition comprising cross-species-specific antibodies and uses thereof
|
|
US8007796B2
(en)
|
2005-12-16 |
2011-08-30 |
Micromet Ag |
Means and methods for the treatment of tumorous diseases
|
|
AU2013202375B2
(en)
*
|
2005-12-16 |
2016-10-27 |
Amgen Research (Munich) Gmbh |
Means and Methods for the Treatment of Tumorous Diseases
|
|
RS53263B
(sr)
|
2006-08-14 |
2014-08-29 |
Xencor Inc. |
Optimizovana antitela usmerena na cd19
|
|
US8323653B2
(en)
|
2006-09-08 |
2012-12-04 |
Medimmune, Llc |
Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
HUE052220T2
(hu)
|
2006-09-08 |
2021-04-28 |
Abbvie Bahamas Ltd |
Interleukin-13 kötõfehérjék
|
|
US9394571B2
(en)
|
2007-04-27 |
2016-07-19 |
Pfenex Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
EP2014680A1
(en)
*
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
|
CN101903403B
(zh)
*
|
2007-10-19 |
2016-03-16 |
西雅图基因公司 |
Cd19结合剂及其应用
|
|
EP2225275A4
(en)
*
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
EP2282769A4
(en)
*
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
EP2297209A4
(en)
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
|
KR20110016959A
(ko)
*
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US8822645B2
(en)
*
|
2008-07-08 |
2014-09-02 |
Abbvie Inc. |
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
|
|
MX2011000501A
(es)
|
2008-07-18 |
2011-05-23 |
Squibb Bristol Myers Co |
Composiciones monovalentes para union a cd28 y metodos de uso.
|
|
AU2009299794B2
(en)
*
|
2008-10-01 |
2015-08-13 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
EP2352763B2
(en)
|
2008-10-01 |
2022-09-21 |
Amgen Research (Munich) GmbH |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
|
MX2011003502A
(es)
*
|
2008-10-01 |
2011-09-01 |
Micromet Ag |
Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
|
|
KR101837053B1
(ko)
*
|
2008-10-01 |
2018-03-12 |
암젠 리서치 (뮌헨) 게엠베하 |
종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체
|
|
JP5798036B2
(ja)
|
2008-11-07 |
2015-10-21 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
小児急性リンパ芽球性白血病の新規治療
|
|
HUE043326T2
(hu)
|
2008-11-07 |
2019-08-28 |
Amgen Res Munich Gmbh |
Akut limfoblasztos leukémia kezelése
|
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
MX2012002651A
(es)
*
|
2009-09-01 |
2012-05-22 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
AR078651A1
(es)
*
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
NZ598732A
(en)
*
|
2009-10-27 |
2014-09-26 |
Amgen Res Munich Gmbh |
Dosage regimen for administering a cd19xcd3 bispecific antibody
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US20130089554A1
(en)
|
2009-12-29 |
2013-04-11 |
Emergent Product Development Seattle, Llc |
RON Binding Constructs and Methods of Use Thereof
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
CN102250245B
(zh)
*
|
2010-05-27 |
2014-05-14 |
四川大学 |
抗b细胞淋巴瘤的双特异性抗体及其用途
|
|
EP2409712A1
(en)
*
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
EP2598530A2
(en)
|
2010-07-29 |
2013-06-05 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
KR20130100118A
(ko)
|
2010-08-03 |
2013-09-09 |
아비에 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US9046513B2
(en)
|
2010-08-26 |
2015-06-02 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
BR112013007293A2
(pt)
|
2010-10-05 |
2016-06-14 |
Hoffmann La Roche |
anticorpos contra a tweak de seres humanos e suas utilizações
|
|
EP3018145B1
(en)
|
2010-10-27 |
2018-04-04 |
Amgen Research (Munich) GmbH |
Means and methods for treating dlbcl
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
CN103533943B
(zh)
|
2010-11-10 |
2018-02-13 |
安进研发（慕尼黑）股份有限公司 |
由cd3特异性结合结构域导致的不良作用的预防
|
|
EP3974453A3
(en)
|
2010-11-16 |
2022-08-03 |
Amgen Inc. |
Agents and methods for treating diseases that correlate with bcma expression
|
|
CN103619876A
(zh)
|
2011-03-10 |
2014-03-05 |
Hco抗体股份有限公司 |
双特异性三链抗体样分子
|
|
ES2806142T3
(es)
|
2011-04-28 |
2021-02-16 |
Amgen Res Munich Gmbh |
Pauta posológica para administrar un anticuerpo biespecífico CD19xCD3 a pacientes en riesgo de posibles efectos adversos
|
|
WO2012162067A2
(en)
|
2011-05-21 |
2012-11-29 |
Macrogenics, Inc. |
Cd3-binding molecules capable of binding to human and non-human cd3
|
|
WO2013048243A1
(en)
*
|
2011-09-29 |
2013-04-04 |
Apo-T B.V. |
Multi-specific binding molecules targeting aberrant cells
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US9574010B2
(en)
|
2011-11-04 |
2017-02-21 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
US9539214B2
(en)
|
2011-12-28 |
2017-01-10 |
Pozen Inc. |
Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
|
|
AR089529A1
(es)
|
2011-12-30 |
2014-08-27 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
|
|
EP2802356A1
(en)
|
2012-01-13 |
2014-11-19 |
Apo-T B.V. |
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
IN2014MN02293A
(enExample)
|
2012-04-20 |
2015-08-07 |
Emergent Product Dev Seattle |
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
KR20150029714A
(ko)
*
|
2012-07-13 |
2015-03-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
|
|
PE20151179A1
(es)
|
2012-11-01 |
2015-09-12 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
|
|
IL282953B2
(en)
*
|
2012-11-13 |
2026-02-01 |
Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh |
Agents for the treatment of claudin-expressing cancers
|
|
US9562110B2
(en)
*
|
2012-11-21 |
2017-02-07 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
US9486475B2
(en)
|
2013-02-08 |
2016-11-08 |
Amgen Research (Munich) Gmbh |
PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
AU2014227732A1
(en)
|
2013-03-15 |
2015-09-17 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 beta and IL-17
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
CN104342453A
(zh)
*
|
2013-08-06 |
2015-02-11 |
深圳先进技术研究院 |
含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
|
EP3054987B1
(en)
|
2013-10-11 |
2019-10-09 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Tem8 antibodies and their use
|
|
LT3074424T
(lt)
|
2013-11-27 |
2025-05-26 |
Zymeworks Bc Inc. |
Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2
|
|
US20150210772A1
(en)
|
2013-12-17 |
2015-07-30 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
|
ES2763429T5
(es)
|
2013-12-17 |
2023-06-21 |
Hoffmann La Roche |
Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
US20160326249A1
(en)
*
|
2014-01-15 |
2016-11-10 |
Zymeworks Inc. |
Bi-specific cd3 and cd19 antigen-binding constructs
|
|
EP3105252B1
(en)
|
2014-02-12 |
2019-07-24 |
Michael Uhlin |
Bispecific antibodies for use in stem cell transplantation
|
|
PL3122781T3
(pl)
|
2014-03-28 |
2020-06-15 |
Xencor, Inc. |
Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
|
|
CN105017422A
(zh)
*
|
2014-04-30 |
2015-11-04 |
山东百因制药技术有限公司 |
一种抗cd3/抗cd19双特异性抗体及其应用
|
|
SI3149480T1
(sl)
|
2014-05-30 |
2019-05-31 |
Amgen Research (Munich) Gmbh |
Stratifikacija tveganj pri bolnikih z akutno limfoblastno levkemijo prekurzorjev b
|
|
MX2016017393A
(es)
|
2014-07-01 |
2017-09-05 |
Pfizer |
Diacuerpos heterodimericos biespecificos y sus usos.
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
BR112017000939A2
(pt)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico de cll-1
|
|
US9611325B2
(en)
|
2014-07-21 |
2017-04-04 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody HER2xCD3
|
|
WO2016036678A1
(en)
*
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
|
CN108064308B
(zh)
|
2014-11-05 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
细菌中产生双链蛋白的方法
|
|
RU2739500C2
(ru)
|
2014-11-05 |
2020-12-25 |
Дженентек, Инк. |
Способы получения двуцепочечных белков в бактериях
|
|
US10160795B2
(en)
|
2014-11-14 |
2018-12-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to Ebola virus glycoprotein and their use
|
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
|
|
HK1245171A1
(zh)
|
2014-11-26 |
2018-08-24 |
Xencor, Inc. |
结合cd3和cd38的异二聚体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
EP3029067A1
(en)
|
2014-12-01 |
2016-06-08 |
Deutsches Krebsforschungszentrum |
Use of blocking-reagents for reducing unspecific T cell-activation
|
|
MX386587B
(es)
|
2014-12-05 |
2025-03-19 |
Genentech Inc |
ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
HRP20240357T1
(hr)
*
|
2014-12-24 |
2024-06-07 |
Autolus Limited |
Stanica
|
|
CN104592393B
(zh)
*
|
2015-01-21 |
2018-09-28 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体cd19×cd3的构建及应用
|
|
AU2016215110A1
(en)
|
2015-02-05 |
2017-09-21 |
Stc.Unm |
Anti-pre-BCR antagonists and methods
|
|
US10301377B2
(en)
|
2015-02-24 |
2019-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
|
SG11201705988UA
(en)
|
2015-02-24 |
2017-08-30 |
Bioatla Llc |
Conditionally active biological proteins
|
|
EP3265567B1
(en)
|
2015-03-02 |
2020-07-29 |
Conagen Inc. |
Regulatory elements from labyrinthulomycetes microorganisms
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
HRP20200583T1
(hr)
|
2015-03-20 |
2020-07-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Protutijela koja neutraliziraju gp120 i njihova upotreba
|
|
EP3292152A1
(en)
|
2015-05-07 |
2018-03-14 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
|
EP3297672B1
(en)
*
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
MX388405B
(es)
|
2015-05-29 |
2025-03-19 |
Genentech Inc |
Un anticuerpo anti-pd-l1 para usarse en el tratamiento de cáncer en sujetos que tienen nivel medio o bajo de metilación en la región promotora pd-l1.
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
HRP20260689T1
(hr)
|
2015-06-17 |
2026-07-17 |
F. Hoffmann-La Roche Ag |
Postupci za liječenje lokalno uznapredovalog ili metastatskog raka dojke primjenom antagonista vezivanja osi pd-1 i taksana
|
|
JP2018524373A
(ja)
|
2015-07-15 |
2018-08-30 |
ザイムワークス，インコーポレイテッド |
薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
|
|
TWI717375B
(zh)
*
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
*
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EP3747472B1
(en)
|
2015-09-15 |
2024-04-03 |
Acerta Pharma B.V. |
Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
|
|
HK1251480A1
(zh)
|
2015-09-21 |
2019-02-01 |
Aptevo Research And Development Llc |
Cd3结合多肽
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3356407B1
(en)
|
2015-10-02 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
EP4011911A1
(en)
|
2015-11-03 |
2022-06-15 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Neutralizing antibodies to hiv-1 gp41 and their use
|
|
WO2017096179A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
TW201720458A
(zh)
*
|
2015-12-04 |
2017-06-16 |
宏觀基因股份有限公司 |
能夠結合cd19 和cd3 的雙特異性單價雙抗體以及其用途
|
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
BR112018011029A2
(pt)
|
2016-01-08 |
2018-11-21 |
Hoffmann La Roche |
métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
|
|
JOP20170017B1
(ar)
*
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
|
AU2017229687A1
(en)
*
|
2016-03-08 |
2018-09-20 |
Takeda Pharmaceutical Company Limited |
Inducible binding proteins and methods of use
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
AU2017235543B2
(en)
*
|
2016-03-16 |
2020-05-14 |
Conagen, Inc. |
Production of proteins in labyrinthulomycetes
|
|
CN109563166B
(zh)
*
|
2016-04-28 |
2022-12-20 |
拜奥穆尼克斯制药 |
靶向egfr和her2的双特异性抗体
|
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
|
CN107365387B
(zh)
*
|
2016-05-12 |
2022-03-15 |
阿思科力(苏州)生物科技有限公司 |
一种双特异性抗原结合构建体及其制备方法和应用
|
|
US11339225B2
(en)
|
2016-05-12 |
2022-05-24 |
Asclepius (Suzhou) Technology Company Group, Co., Ltd. |
Bispecific antigen-binding construct and preparation method and use thereof
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
IL299221A
(en)
|
2016-06-21 |
2023-02-01 |
Teneobio Inc |
Cd3 binding antibodies
|
|
RU2019102008A
(ru)
|
2016-06-28 |
2020-07-28 |
Ксенкор, Инк. |
Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
|
|
EP3478722A1
(en)
*
|
2016-06-30 |
2019-05-08 |
F. Hoffmann-La Roche AG |
Improved adoptive t-cell therapy
|
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CR20220578A
(es)
|
2016-09-14 |
2023-01-17 |
Teneobio Inc |
Anticuerpos de unión a cd3
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
US10633454B2
(en)
|
2016-11-01 |
2020-04-28 |
Conagen Inc. |
Expression of modified glycoproteins and glycopeptides
|
|
CA3041340A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
CA3042613A1
(en)
*
|
2016-11-11 |
2018-05-17 |
Autolus Limited |
Chimeric antigen receptor
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
JP7125400B2
(ja)
|
2016-12-19 |
2022-08-24 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
|
|
KR102692708B1
(ko)
|
2016-12-20 |
2024-08-07 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
|
|
EP3559035A1
(en)
|
2016-12-21 |
2019-10-30 |
TeneoBio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
CN108264559B
(zh)
*
|
2016-12-30 |
2021-08-10 |
惠和生物技术(上海)有限公司 |
一种结合cd19、cd3和t细胞正共刺激分子的三功能分子及其应用
|
|
EP3575319A4
(en)
*
|
2016-12-30 |
2021-03-10 |
Shanghai Sinobio Biotech Co., Ltd. |
BIFUNCTIONAL MOLECULE AND USE OF IT
|
|
CN108264561B
(zh)
*
|
2016-12-30 |
2021-09-10 |
惠和生物技术(上海)有限公司 |
一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
|
|
CN106589129B
(zh)
*
|
2016-12-30 |
2021-03-05 |
上海近岸生物科技有限公司 |
一种结合cd19、cd3和cd28的三功能分子及其应用
|
|
US11535666B2
(en)
*
|
2016-12-30 |
2022-12-27 |
Cytocares (Shanghai) Inc. |
Trifunctional molecule and application thereof
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
EP3580235B1
(en)
|
2017-02-10 |
2024-05-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
EP4273258A3
(en)
|
2017-02-20 |
2024-01-17 |
Dragonfly Therapeutics, Inc. |
Proteins binding her2, nkg2d and cd16
|
|
AU2018241881B2
(en)
*
|
2017-03-27 |
2024-10-10 |
Biomunex Pharmaceuticals |
Stable multispecific antibodies
|
|
PE20200010A1
(es)
|
2017-04-03 |
2020-01-06 |
Hoffmann La Roche |
Anticuerpos que se unen a steap-1
|
|
JP2020521791A
(ja)
|
2017-06-02 |
2020-07-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体
|
|
CN110891971B
(zh)
|
2017-06-20 |
2024-01-12 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
JP7240335B2
(ja)
|
2017-06-20 |
2023-03-15 |
テネオワン， インコーポレイテッド |
抗ｂｃｍａ重鎖のみ抗体
|
|
JP7009517B2
(ja)
|
2017-06-21 |
2022-01-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
WO2019011918A1
(en)
|
2017-07-10 |
2019-01-17 |
International - Drug - Development - Biotech |
TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
|
|
US11525004B2
(en)
|
2017-07-20 |
2022-12-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Recombinant CD123-binding antibodies
|
|
JP7801095B2
(ja)
|
2017-08-01 |
2026-01-16 |
エイビー セラピューティクス インコーポレイテッド |
二重特異性抗体およびその使用
|
|
CN118126157A
(zh)
|
2017-08-03 |
2024-06-04 |
美国安进公司 |
白介素-21突变蛋白和治疗方法
|
|
AU2018314236B2
(en)
|
2017-08-11 |
2025-02-06 |
Apterna Limited |
RNA aptamers against transferrin receptor (TfR)
|
|
CN111356700A
(zh)
|
2017-09-08 |
2020-06-30 |
马弗里克治疗公司 |
受约束的条件性活化的结合蛋白
|
|
US10640504B2
(en)
|
2017-09-08 |
2020-05-05 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
|
EA202090565A1
(ru)
|
2017-10-13 |
2020-10-13 |
Мерк Шарп энд Доум Корп. |
Композиции и способы лечения диффузной в-крупноклеточной лимфомы
|
|
EP3704155A2
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Combination therapy with targeted ox40 agonists
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US12564632B2
(en)
*
|
2017-11-08 |
2026-03-03 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
Conjugates of biomolecule and use thereof
|
|
US11795226B2
(en)
|
2017-12-12 |
2023-10-24 |
Macrogenics, Inc. |
Bispecific CD16-binding molecules and their use in the treatment of disease
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたｉｌ－２ ｆｃ融合タンパク質
|
|
PE20201149A1
(es)
|
2017-12-21 |
2020-10-26 |
Hoffmann La Roche |
Anticuerpos de union a hla-a2/wt1
|
|
IL275462B2
(en)
|
2017-12-22 |
2026-01-01 |
Genentech Inc |
Targeted integration of nucleic acids
|
|
EP3732199A1
(en)
|
2017-12-27 |
2020-11-04 |
TeneoBio, Inc. |
Cd3-delta/epsilon heterodimer specific antibodies
|
|
US11976109B2
(en)
|
2018-01-02 |
2024-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
MX2020007291A
(es)
|
2018-01-12 |
2020-09-10 |
Amgen Inc |
Anticuerpos anti-pd-1 y metodos de tratamiento.
|
|
JP2021511782A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
安定化された免疫グロブリンドメイン
|
|
JP2021511793A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
|
|
MX2020008333A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
|
|
CA3090244A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
CN111787949A
(zh)
|
2018-02-15 |
2020-10-16 |
宏观基因有限公司 |
变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
|
|
CN112119093A
(zh)
|
2018-02-20 |
2020-12-22 |
蜻蜓治疗公司 |
结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
|
|
CN111971299A
(zh)
|
2018-02-21 |
2020-11-20 |
美国政府(由卫生和人类服务部的部长所代表) |
HIV-1 Env的中和抗体及其用途
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
PL3765489T3
(pl)
|
2018-03-13 |
2025-02-10 |
F. Hoffmann-La Roche Ag |
Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
|
|
JP2021519073A
(ja)
|
2018-03-29 |
2021-08-10 |
ジェネンテック， インコーポレイテッド |
哺乳動物細胞におけるラクトジェニック活性の制御
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
FI3817770T3
(fi)
|
2018-07-02 |
2026-07-06 |
Amgen Inc |
Antigeeniä sitova anti-steap1-proteiini
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
CA3108427A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
CN113164570B
(zh)
|
2018-08-08 |
2024-05-14 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
WO2020052543A1
(en)
|
2018-09-10 |
2020-03-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against cd33 and constructs thereof
|
|
TWI846731B
(zh)
|
2018-09-18 |
2024-07-01 |
瑞士商赫孚孟拉羅股份公司 |
組織蛋白酶(cathepsin)S抑制劑之對抗抗藥抗體形成之用途
|
|
AU2019342133B8
(en)
|
2018-09-21 |
2025-08-07 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
CN113260626B
(zh)
|
2018-11-05 |
2024-09-13 |
豪夫迈·罗氏有限公司 |
在原核宿主细胞中产生双链蛋白质的方法
|
|
EP3883609A2
(en)
|
2018-12-20 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
|
CR20210326A
(es)
|
2018-12-21 |
2021-09-10 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
|
|
SG11202102859TA
(en)
|
2018-12-21 |
2021-04-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
|
EP3980544A1
(en)
|
2018-12-21 |
2022-04-13 |
F. Hoffmann-La Roche AG |
Targeted integration of nucleic acids
|
|
WO2020141145A1
(en)
|
2018-12-30 |
2020-07-09 |
F. Hoffmann-La Roche Ag |
Anti-rabbit cd19 antibodies and methods of use
|
|
BR112021013193A2
(pt)
*
|
2019-01-07 |
2021-09-28 |
Shattuck Labs, Inc. |
Proteínas heterodiméricas para modulação de células t gama delta
|
|
MX2021008561A
(es)
|
2019-01-23 |
2021-08-19 |
Genentech Inc |
Metodos de produccion de proteinas multimericas en celulas huesped eucariotas.
|
|
CN113660956B
(zh)
|
2019-01-28 |
2024-10-29 |
Ab诊疗公司 |
双特异性抗体及其用途
|
|
EP3930850A1
(en)
|
2019-03-01 |
2022-01-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
EP4592313A3
(en)
|
2019-03-05 |
2025-11-19 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
CN109776683B
(zh)
*
|
2019-03-19 |
2020-04-07 |
益科思特(北京)医药科技发展有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
CA3133654A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
WO2020221792A1
(en)
|
2019-04-30 |
2020-11-05 |
Amgen Research (Munich) Gmbh |
Means and methods of treating burkitt lymphoma or leukemia
|
|
WO2020227228A2
(en)
|
2019-05-03 |
2020-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
JP7137696B2
(ja)
|
2019-05-14 |
2022-09-14 |
プロヴェンション・バイオ・インコーポレイテッド |
１型糖尿病を予防するための方法および組成物
|
|
CN118359709A
(zh)
|
2019-05-21 |
2024-07-19 |
佐治亚大学研究基金会有限公司 |
结合人类偏肺病毒融合蛋白的抗体及其用途
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
AU2020279224B2
(en)
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
CN114206927B
(zh)
|
2019-06-14 |
2025-03-21 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
MX2022000174A
(es)
|
2019-07-02 |
2022-05-20 |
Us Health |
Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
|
|
WO2021018925A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
JP2022543553A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｇｐｒｃ５ｄに結合する抗体
|
|
CN110577603B
(zh)
*
|
2019-08-15 |
2021-12-28 |
北京东方百泰生物科技股份有限公司 |
一种抗cd3和抗cd19双特异性抗体
|
|
AU2020331963A1
(en)
*
|
2019-08-19 |
2022-03-03 |
Elpis Biopharmaceuticals |
Anti-CD19 antibodies and uses thereof
|
|
WO2021041300A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
AU2020349509A1
(en)
|
2019-09-18 |
2022-03-31 |
Genentech, Inc. |
Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
|
|
CN115916818A
(zh)
|
2019-12-11 |
2023-04-04 |
库利南肿瘤股份有限公司 |
抗cd19抗体和多特异性结合蛋白
|
|
CN114828965B
(zh)
|
2019-12-18 |
2025-09-05 |
豪夫迈·罗氏有限公司 |
与hla-a2/mage-a4结合的抗体
|
|
CN115515678A
(zh)
|
2019-12-23 |
2022-12-23 |
基因泰克公司 |
载脂蛋白l1特异性抗体及其使用方法
|
|
CN115279406A
(zh)
|
2020-01-13 |
2022-11-01 |
阿帕特夫研究和发展有限公司 |
蛋白质治疗剂的调配物
|
|
US20230151102A1
(en)
|
2020-01-13 |
2023-05-18 |
Aptevo Research And Development Llc |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
|
EP3865513A1
(en)
|
2020-02-17 |
2021-08-18 |
Fundación Para La Investigación Biomédica Del Hospital 12 De Octubre |
Anti-cd19/anti-cd3 bispecific antibody, t cells secreting the same, method of preparation and use thereof
|
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
US12098365B2
(en)
|
2020-03-26 |
2024-09-24 |
Genentech, Inc. |
Modified mammalian cells
|
|
MX2022013173A
(es)
|
2020-04-24 |
2022-11-30 |
Hoffmann La Roche |
Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados.
|
|
KR20250007022A
(ko)
|
2020-04-29 |
2025-01-13 |
테네오원, 인코포레이티드 |
변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
|
|
AU2021268340A1
(en)
|
2020-05-06 |
2022-12-08 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
EP4149632A1
(en)
|
2020-05-14 |
2023-03-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
CA3184495A1
(en)
|
2020-06-08 |
2021-12-16 |
F. Hoffmann-La Roche Ag |
Anti-hbv antibodies and methods of use
|
|
KR20230092863A
(ko)
|
2020-06-11 |
2023-06-26 |
프로벤션 바이오, 인코포레이티드 |
제1형 당뇨병을 예방하기 위한 방법 및 조성물
|
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
AR122656A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 / folr1
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
CR20220637A
(es)
|
2020-06-19 |
2023-01-31 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y cd19
|
|
IL296089A
(en)
|
2020-06-19 |
2022-11-01 |
Hoffmann La Roche |
Antibodies bind to cd3
|
|
KR20230027043A
(ko)
|
2020-06-24 |
2023-02-27 |
제넨테크, 인크. |
핵산의 표적화 통합
|
|
EP4172192A1
(en)
|
2020-06-24 |
2023-05-03 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
|
CA3185122A1
(en)
|
2020-07-17 |
2022-01-20 |
Cecilia Pui Chi Chiu |
Anti-notch2 antibodies and methods of use
|
|
WO2022018262A1
(en)
*
|
2020-07-24 |
2022-01-27 |
Cellectis S.A. |
T-cells expressing immune cell engagers in allogenic settings
|
|
JP2023536100A
(ja)
*
|
2020-07-27 |
2023-08-23 |
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ |
代替の翻訳開始および翻訳停止に由来する多機能免疫グロブリンフォールドポリペプチド
|
|
US20240059797A1
(en)
*
|
2020-07-29 |
2024-02-22 |
Gritstone Bio, Inc. |
Engineered multi-specific antibodies and related methods of use and manufacture
|
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
WO2022045247A1
(ja)
|
2020-08-27 |
2022-03-03 |
学校法人順天堂 |
抗切断型変異ｃａｌｒ－ｃｄ３二重特異性抗体及び医薬組成物
|
|
JP2023539201A
(ja)
|
2020-08-28 |
2023-09-13 |
ジェネンテック， インコーポレイテッド |
宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
|
|
WO2022082030A2
(en)
|
2020-10-15 |
2022-04-21 |
Gritstone Bio, Inc. |
Antigen-binding proteins and related methods of use
|
|
JP2023550148A
(ja)
|
2020-11-20 |
2023-11-30 |
シンシア・イノベーション・インコーポレイテッド |
がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法
|
|
WO2022129120A1
(en)
|
2020-12-17 |
2022-06-23 |
F. Hoffmann-La Roche Ag |
Anti-hla-g antibodies and use thereof
|
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
|
WO2022155503A1
(en)
|
2021-01-14 |
2022-07-21 |
Gritstone Bio, Inc. |
Multi-specific antibodies and methods of use
|
|
CA3202891A1
(en)
|
2021-01-28 |
2022-08-04 |
Kara Olson |
Compositions and methods for treating cytokine release syndrome
|
|
EP4288458A1
(en)
|
2021-02-03 |
2023-12-13 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
AU2022218137A1
(en)
|
2021-02-03 |
2023-08-24 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
CN117396502A
(zh)
|
2021-02-09 |
2024-01-12 |
佐治亚大学研究基金会有限公司 |
针对肺炎球菌抗原的人类单克隆抗体
|
|
AU2022221297A1
(en)
|
2021-02-09 |
2023-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies targeting the spike protein of coronaviruses
|
|
MX2023009433A
(es)
|
2021-02-16 |
2023-11-29 |
Children´S Health Care D/B/A/ Children´S Minnesota |
Metodos para el tratamiento de b-all mediante la administracion de un antagonista del complejo pre-bcr.
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
EP4304732A1
(en)
|
2021-03-12 |
2024-01-17 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
WO2022217022A1
(en)
|
2021-04-10 |
2022-10-13 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
JP2024514222A
(ja)
|
2021-04-19 |
2024-03-28 |
ジェネンテック， インコーポレイテッド |
改変された哺乳動物細胞
|
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
WO2022228706A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
US20240262920A1
(en)
|
2021-05-21 |
2024-08-08 |
Aptevo Research And Development Llc |
Dosing regimens for protein therapeutics
|
|
CN117396599A
(zh)
|
2021-05-21 |
2024-01-12 |
基因泰克公司 |
用于生产目的重组产物的经修饰的细胞
|
|
MX2023013851A
(es)
|
2021-05-24 |
2023-12-08 |
Provention Bio Inc |
Metodos para el tratamiento de diabetes tipo 1.
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
WO2023287663A1
(en)
|
2021-07-13 |
2023-01-19 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
|
JP2024528631A
(ja)
|
2021-07-22 |
2024-07-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
ヘテロ二量体Ｆｃドメイン抗体
|
|
JP2024528217A
(ja)
|
2021-08-03 |
2024-07-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗体および使用方法
|
|
US20240360233A1
(en)
|
2021-08-27 |
2024-10-31 |
Board Of Regents, The University Of Texas System |
Anti-tslpr (crlf2) antibodies
|
|
AU2022345251A1
(en)
|
2021-09-17 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
|
|
KR20240099263A
(ko)
|
2021-10-15 |
2024-06-28 |
암젠 리서치 (뮌헨) 게엠베하 |
Cd19 결합 t 세포 관여 항체의 피하 투여
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
|
CA3251161A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
|
AU2023226293A1
(en)
|
2022-02-25 |
2024-09-05 |
Juntendo Educational Foundation |
Medicine comprising combination of anti-mutant-calr antibody and another drug
|
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
CN116925234B
(zh)
*
|
2022-04-02 |
2024-05-31 |
合肥星眸生物科技有限公司 |
一种编码抗vegf-a和ang-2双特异性抗体的aav载体
|
|
AU2023254191A1
(en)
|
2022-04-11 |
2024-10-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
|
CN119654349A
(zh)
|
2022-07-22 |
2025-03-18 |
基因泰克公司 |
抗steap1抗原结合分子及其用途
|
|
EP4565329A1
(en)
|
2022-08-01 |
2025-06-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
US20260092121A1
(en)
|
2022-10-14 |
2026-04-02 |
Talem Therapeutics Llc |
Anti-trkb/cd3 antibodies and uses thereof
|
|
WO2024097218A1
(en)
*
|
2022-11-01 |
2024-05-10 |
TeneoTwo, Inc. |
Methods of treating non-hodgkin lymphoma
|
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
|
WO2024107879A1
(en)
|
2022-11-15 |
2024-05-23 |
Genentech, Inc. |
Combined transposon-mediated integration and targeted integration of nucleic acids into host cells
|
|
EP4634397A1
(en)
|
2022-12-12 |
2025-10-22 |
Genentech Inc. |
Optimizing polypeptide sialic acid content
|
|
WO2024137381A1
(en)
|
2022-12-19 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies for treating sars-cov-2 infection
|
|
WO2024138151A1
(en)
|
2022-12-22 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
|
|
JP2026502534A
(ja)
|
2023-01-12 |
2026-01-23 |
ジェネンテック， インコーポレイテッド |
核酸の標的組込みのためのコンビナトリアルベクターのクローニングおよびトランスフェクション戦略
|
|
EP4655322A1
(en)
|
2023-01-25 |
2025-12-03 |
F. Hoffmann-La Roche AG |
Antibodies binding to csf1r and cd3
|
|
AU2024223918A1
(en)
|
2023-02-17 |
2025-09-11 |
Regeneron Pharmaceuticals, Inc. |
Induced nk cells responsive to cd3/taa bispecific antibodies
|
|
CN120826234A
(zh)
|
2023-03-06 |
2025-10-21 |
豪夫迈·罗氏有限公司 |
抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
|
|
EP4676951A1
(en)
|
2023-03-10 |
2026-01-14 |
Genentech Inc. |
Fusions with proteases and uses thereof
|
|
WO2024188966A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4‑1bb (cd137) agonist
|
|
KR20250167591A
(ko)
|
2023-03-31 |
2025-12-01 |
제넨테크, 인크. |
항-알파 v 베타 8 인테그린 항체 및 사용 방법
|
|
AU2024269754A1
(en)
|
2023-05-08 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Targeted interferon alpha fusion proteins and methods of use
|
|
EP4720124A1
(en)
|
2023-05-24 |
2026-04-08 |
Mozart Therapeutics, Inc. |
Cd8-specific binding proteins and methods of using the same
|
|
WO2024243355A1
(en)
|
2023-05-24 |
2024-11-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
|
|
WO2024261013A1
(en)
|
2023-06-21 |
2024-12-26 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|
|
JP2026522631A
(ja)
|
2023-06-22 |
2026-07-08 |
ジェネンテック， インコーポレイテッド |
抗体及びその使用
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
EP4747276A1
(en)
|
2023-07-21 |
2026-05-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Bispecific antibodies that broadly target coronaviruses
|
|
PE20260581A1
(es)
|
2023-07-26 |
2026-03-11 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
IL327717A
(en)
|
2023-10-18 |
2026-06-01 |
Genentech Inc |
Retroviral-like particle-reduced chinese hamster ovary production cell lines
|
|
WO2025106427A1
(en)
|
2023-11-14 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
|
|
AU2024388998A1
(en)
|
2023-11-27 |
2026-05-28 |
Genmab A/S |
Antibodies and methods for ptk7 detection
|
|
WO2025117384A1
(en)
|
2023-12-01 |
2025-06-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing influenza hemagglutinin stem-directed antibodies
|
|
CN122459340A
(zh)
|
2023-12-14 |
2026-07-24 |
豪夫迈·罗氏有限公司 |
与folr1结合的抗体及使用方法
|
|
WO2025137086A1
(en)
|
2023-12-20 |
2025-06-26 |
Genentech, Inc. |
Reducing alpha-gal
|
|
CN122422356A
(zh)
|
2023-12-20 |
2026-07-17 |
豪夫迈·罗氏有限公司 |
与ceacam5结合的抗体
|
|
IL328694A
(en)
|
2023-12-21 |
2026-07-01 |
Us Health |
Broad neutralizing antibodies against SARS-COV-2 and SARS-COV variants
|
|
AU2024402334A1
(en)
|
2023-12-22 |
2026-05-28 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
TW202547866A
(zh)
|
2024-01-10 |
2025-12-16 |
丹麥商珍美寶股份有限公司 |
Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
AU2025227506A1
(en)
|
2024-03-01 |
2026-08-13 |
Amgen Research (Munich) Gmbh |
Cd19-selective t cell engaging molecule for treating autoimmune diseases/ autoimmune conditions
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
CN121311509A
(zh)
*
|
2024-04-09 |
2026-01-09 |
艾博生命科学(上海)有限公司 |
Cd3和cd19的结合剂、编码其的核酸及其用途
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025222129A2
(en)
|
2024-04-19 |
2025-10-23 |
Mozart Therapeutics, Inc. |
Engineered cytokines and targeted cytokine delivery
|
|
WO2025233266A1
(en)
|
2024-05-07 |
2025-11-13 |
Innate Pharma |
Use of cd39 blocking agents in combination with anti-cd20 x cd3 t cell engagers
|
|
WO2025233264A1
(en)
|
2024-05-07 |
2025-11-13 |
Innate Pharma |
Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers
|
|
WO2026006162A2
(en)
|
2024-06-24 |
2026-01-02 |
Genentech, Inc. |
B vitamin modulation
|
|
WO2026030473A1
(en)
|
2024-07-31 |
2026-02-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
West nile virus neutralizing monoclonal antibodies
|
|
WO2026032438A1
(zh)
*
|
2024-08-08 |
2026-02-12 |
惠和生物技术(上海)有限公司 |
多特异性抗体治疗自身免疫性疾病的用途
|
|
WO2026041568A1
(en)
|
2024-08-20 |
2026-02-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and dotam
|
|
WO2026128512A1
(en)
|
2024-12-09 |
2026-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies to nipah virus and their use
|
|
WO2026132145A1
(en)
|
2024-12-20 |
2026-06-25 |
F. Hoffmann-La Roche Ag |
Antibodies binding to tn-muc-1
|
|
WO2026132383A2
(en)
|
2024-12-20 |
2026-06-25 |
F. Hoffmann-La Roche Ag |
ANTIBODIES BINDING TO Tn-MUC-1
|
|
WO2026159103A1
(en)
|
2025-01-23 |
2026-07-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|